Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Mechanisms contributing to reduced cytotoxic drug accumulation were studied in two multidrug-resistant (MDR) human lung cancer cell lines without P-glycoprotein expression. In these (non-small cell) SW-1573/2R120 and (small cell) GLC4/ADR MDR cells, the steady-state accumulation of [14C]daunorubicin was 30 and 12%, respectively, of that in the parent cells. When cells, at steady state, were permeabilized with digitonin, the amount of daunorubicin binding increased only in the resistant cells. The reduced accumulation of daunorubicin in the SW-1573/2R120 and GLC4/ADR cells was accompanied by a lower initial (2 min) uptake rate of this drug. No difference in initial efflux rate of daunorubicin from preloaded cells could be detected between sensitive and resistant SW-1573 cells. However, daunorubicin was extruded 5-fold faster from GLC4/ADR cells than from the parental cells. In the presence of the energy metabolism inhibitors sodium azide and deoxyglucose, the reduced daunorubicin accumulations in the SW-1573/2R120 and GLC4/ADR MDR cells were (almost) completely reversed. The effects of these inhibitors on drug uptake were already apparent during the earliest measured time points (less than 15 s). Also, the enhanced efflux of daunorubicin from GLC4/ADR cells was inhibited. In ATP-depleted cells, the intracellular pH was lowered by approximately 0.3 units in resistant as well as in sensitive cells. The lower intracellular pH, however, could not account for the increase in daunorubicin accumulation in the resistant cells. Also, for vincristine and etoposide, the increases in drug accumulation under energy-deprived conditions were more pronounced in the resistant SW-1573/2R120 cells than in the parent SW-1573 cells. These results suggest that accumulation of drugs in the non-P-glycoprotein MDR human lung carcinoma cell lines SW-1573/2R120 and GLC4/ADR is reduced by an energy-dependent drug export mechanism which prevents efficient transport of drug to the target. Since P-glycoprotein expression in lung tumors is generally low, these MDR lung cancer cell lines can be used as a model to study alternative mechanisms leading to multidrug resistance in this tumor type.
Versantvoort
C H
CH
Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
Broxterman
H J
HJ
Pinedo
H M
HM
de Vries
E G
EG
Feller
N
N
Kuiper
C M
CM
Lankelma
J
J
D000255:Adenosine Triphosphate / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism*; D002463:Cell Membrane Permeability; D003630:Daunorubicin / Q000378:metabolism*; D004351:Drug Resistance / Q000235:genetics / Q000502:physiology; D004734:Energy Metabolism; D005047:Etoposide / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism*; D009550:Nigericin / Q000494:pharmacology; D010641:Phenotype; D012333:RNA, Messenger / Q000032:analysis* / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000378:metabolism; D014750:Vincristine / Q000378:metabolism*
D012333:RNA, Messenger; D014750:Vincristine; D005047:Etoposide; D000255:Adenosine Triphosphate; D009550:Nigericin; D003630:Daunorubicin